From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses the emerging geopolitical battle for ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Strand Therapeutics' lead asset is STX-001, an intra-tumor self-replicating mRNA therapy that carries a payload expressing ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for ...

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...